Testicular Regression Syndrome Revisited: Insights from a 15-Year Retrospective Study and Evolving Perspectives on Management

In 262 boys with absent testes, only 1.1% of remnants contained viable germ cells — and no malignancy was found in 15 years.

Journal: Journal of Pediatric Urology | Published: 2026-02-14 | Type: Retrospective Cohort | PMID: 41747307 Authors: Thomas CS, Dmello L, Jacob TJK, Loganathan AK — Department of Paediatric Surgery, Christian Medical College and Hospital, Vellore, India Funding/COI: Funding not listed; no conflicts of interest declared

Summary

Testicular Regression Syndrome (TRS) is what happens when a testis vanishes before birth, leaving behind a fibrous cord remnant where testicular tissue should be. The standard of care has been to surgically excise those remnants on the assumption they carry malignant potential — but this 15-year single-centre review of 262 boys challenges the urgency of that blanket approach. Viable germ cells turned up in just 1.1% of specimens, and no invasive malignancy appeared anywhere in the cohort. Location matters: intra-abdominal remnants were far more likely to contain concerning tissue than inguinal or scrotal ones.

Claims

• 262 children with clinically impalpable testes underwent diagnostic laparoscopy and/or inguinal exploration between 2008 and 2022; median age at surgery was 3 years
• 83% of remnants were left-sided; intra-abdominal location in 5% of cases
• Vas deferens identified histologically in 86% of specimens; epididymal tissue in 66%
• Seminiferous tubules (SNTs) found in 10.3% of all remnants; viable germ cells (GCs) in only 1.1%
• Intra-abdominal remnants: 62% contained SNTs or GCs vs. 10% inguinal vs. 4% scrotal (p < 0.0001)
• Calcifications and hemosiderin deposits — markers of in-utero regression — found in 29%
• Zero cases of invasive malignancy in the entire 15-year series

Study Quality

This is a retrospective single-centre review, which caps how far its conclusions can travel. The sample of 262 is respectable for a rare condition, and the 15-year span provides genuine longitudinal depth. Histopathological examination was systematic, with all excised remnants assessed for SNTs, viable GCs, and regression features — that consistency strengthens the internal validity of the tissue-type findings. The p-value for the location-dependent difference in SNT/GC prevalence (p < 0.0001) is robust.

The study's primary limitation is what it cannot tell us: follow-up duration for individual patients isn't reported, so the claim that "no invasive malignancy has been reported" reflects the observation period at this centre, not a lifetime risk calculation. Selection bias is also present — only children who underwent surgery are included, so boys managed conservatively or lost to follow-up aren't represented.

Red Flags

• Retrospective design: no standardised pre-operative workup protocol across 15 years, and management likely evolved over that window
• Funding source not declared — for a surgical centre publishing in favour of selective (rather than universal) excision, transparency on this would help
• No individual patient follow-up duration reported; "no malignancy observed" is not the same as "no malignancy risk"
• Single tertiary centre in India — referral patterns mean this is not a population-based sample; case mix may skew toward more complex presentations
• The 5% intra-abdominal rate seems low relative to published literature, raising a question about whether all impalpable testes were fully characterised before classification as TRS

Strengths

• Largest single-centre TRS series in recent literature at 262 cases
• Systematic histopathology on all excised specimens, not just selected ones
• Clear stratification by anatomical location with a statistically significant finding that has direct clinical implications
• 15-year span reduces the chance that the zero-malignancy finding is a short-term artefact

Verdict

This paper does useful work. The 1.1% viable germ cell rate is the number that matters, and it lands a direct blow against the reflexive "excise everything" dogma that has governed TRS management. The location-stratified risk data (62% vs. 10% vs. 4%) is the paper's strongest contribution — it gives clinicians a principled basis for differentiating intra-abdominal from inguino-scrotal remnants rather than treating all TRS identically. The absence of malignancy over 15 years is reassuring but not conclusive: the follow-up architecture isn't there to make it a definitive safety claim. Worth reading for the histopathological data; treat the management conclusions as hypothesis-generating, not practice-changing, until prospective data exists.